Ovarian Reserve in Crohn's Disease

Evaluation of Ovarian Reserve in Crohn's Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03897400

Enrollment

100

Registered

2019-04-01

Start date

2019-03-01

Completion date

2019-09-01

Last updated

2019-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anti-Mullerian Hormone Deficiency, Crohn Disease, Ovary Disease

Brief summary

Crohn's disease reduces fertility by inducing inflammation both directly and in the fallopian tubes and ovaries and indirectly through surgical interventions and tubal adhesions associated with disease treatment. Anti-mullerian hormone (AMH) is a reliable indicator of ovarian reserve in women. The aim of this study was to compare serum AMH levels in women with Crohn's disease and healthy controls. In this study, the investigators aimed to investigate AMH and ovarian capacity in the study group with crohn's disease and in the control group without disease.

Interventions

OTHERAMH levels in young women with crohn's disease will be considered.

Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* crohn's disease; * reproductive age women

Exclusion criteria

* Over 40 years old, * a previous ovarian resection; * renal failure (serum creatinine levels N1.2 mg / dL);suspicion of malignancy; * the presence of hereditary or acquired hematological disease; * pregnancy; * current lactation; * the presence of a serious comorbid chronic disease; * cirrhosis originating from chronic liver disease; * abnormal thyroid function tests; * a known serious psychological problem; * presence of alcoholism and male sex.

Design outcomes

Primary

Measure	Time frame	Description
AMH levels	1 MONTH	AMH levels of subjects taken into groups will be evaluated in lg/L

Secondary

Measure	Time frame	Description
ultrasound findings	1 MONTH	On the 3rd day of the menstrual cycle, the patients will be given ultrasound and the ovarian volume will be examined. the ovarian volume will be calculated by taking the size of the ovary in three sections.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026